Wednesday - October 07, 2026

VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs

Dallas TX – Sept. 28, 2026 – VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant testing technologies designed to identify unsuccessful drug candidates earlier, potentially improving the economics of pharmaceutical development. With an industry clinical-trial success rate of approximately 8%, the effective cost … Continue reading →